Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 11, 2013, Pages 4351-4356

  Julien, Jean Philippe ^a   Lee, Jeong Hyun ^a   Cupo, Albert ^b   Murin, Charles D ^a   Derking, Ronald ^c   Hoffenberg, Simon ^d   Caulfield, Michael J ^d   King, C Richter ^d   Marozsan, Andre J ^b   Klasse, Per Johan ^b   Sanders, Rogier W ^b,c   Moore, John P ^b   Wilson, Ian A ^a,e   Ward, Andrew B ^a  

^a Department of Integrative Structural and Computational Biology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 20; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY PG9; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; ELECTRON MICROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; LIGHT SCATTERING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; X-RAY DIFFRACTION;

EID: 84875034460     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217537110     Document Type: Article

References (59)

1. Simek MD, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 83(14):7337-7348.
2. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289.
3. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049):1593-1602.
4. Scheid JF, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049):1633-1637.
5. Mouquet H, et al. (2011) Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 6(9):e24078.
6. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470.
7. Kwong PD, Mascola JR, Nabel GJ (2009) Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1. Cell Host Microbe 6(4):292-294.
8. Clapham PR, Lu S (2011) Vaccinology: Precisely tuned antibodies nab HIV. Nature 477(7365):416-417.
9. Overbaugh J, Morris L (2012) The antibody response against HIV-1. Cold Spring Harb Perspect Med 2(1):a007039.
10. Burton DR, Poignard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183-186.
11. Julien JP, Lee PS, Wilson IA (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 250(1):180-198.
12. Conley AJ, et al. (1996) The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 70(10):6751-6758.
13. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15(8):951-954.
14. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5(5):e1000433.
15. Hessell AJ, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84(3):1302-1313.
16. Mascola JR (2003) Defining the protective antibody response for HIV-1. Curr Mol Med 3(3):209-216.
17. Karlsson Hedestam GB, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6(2):143-155.
18. Korber B, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58:19-42.
19. Korber B, et al. (2000) Timing the ancestor of the HIV-1 pandemic strains. Science 288(5472):1789-1796.
20. McCaffrey RA, Saunders C, Hensel M, Stamatatos L (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78(7):3279-3295.
21. Li Y, et al. (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82(2):638-651.
22. Binley JM, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84(11): 5637-5655.
23. Johnson WE, Desrosiers RC (2002) Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 53:499-518.
24. Wyatt R, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686):705-711.
25. Doria-Rose NA, et al. (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83(1):188-199.
26. Sather DN, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83(2):757-769.
27. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat Med 15(8):866-870.
28. Euler Z, et al. (2010) Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201(7):1045-1053.
29. Piantadosi A, et al. (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83(19):10269-10274.
30. Pancera M, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84(16):8098-8110.
31. Pejchal R, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 107(25):11483-11488.
32. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480(7377):336-343.
33. Moore PL, et al.; CAPRISA 002 Study (2011) Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 85(7):3128-3141.
34. Depetris RS, et al. (2012) Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 287(29): 24239-24254.
35. Sanders RW, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76(17):8875-8889.
36. Phogat SK, et al. (2011) US Patent 20110262488.
37. Humes D, Overbaugh J (2011) Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J Virol 85(9):4409-4420.
38. Putnam CD, Hammel M, Hura GL, Tainer JA (2007) X-ray solution scattering (SAXS) combined with crystallography and computation: Defining accurate macromolecular structures, conformations and assemblies in solution. Q Rev Biophys 40(3):191-285.
39. Tran EE, et al. (2012) Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8(7):e1002797.
40. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455(7209):109-113.
41. Pejchal R, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334(6059):1097-1103.
42. Harris A, et al. (2011) Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci USA 108(28):11440-11445.
43. Doores KJ, Burton DR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84(20):10510-10521.
44. Reeves PJ, Callewaert N, Contreras R, Khorana HG (2002) Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci USA 99(21):13419-13424.
45. Bonomelli C, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 6(8):e23521.
46. Doores KJ, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA 107(31):13800-13805.
47. Eggink D, et al. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401(2):236-247.
48. Doria-Rose NA, et al. (2012) A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 86(15): 8319-8323.
49. Davenport TM, et al. (2011) Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J Virol 85(14):7095-7107.
50. Leavitt SA, et al. (2004) Interactions of HIV-1 proteins gp120 and Nef with cellular partners define a novel allosteric paradigm. Curr Protein Pept Sci 5(1):1-8.
51. Brower ET, Schön A, Freire E (2010) Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 49(11): 2359-2367.
52. Konarev PV, et al. (2003) PRIMUS - a Windows-PC based system for small-angle scattering data analysis. J Appl Cryst 36:1277-1282.
53. Svergun DI, Petoukhov MV, Koch MH (2001) Determination of domain structure of proteins from X-ray solution scattering. Biophys J 80(6):2946-2953.
54. Volkov VV, Svergun DI (2003) Uniqueness of ab-initio shape determination in smallangle scattering. J Appl Cryst 36:860-864.
55. van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M (1996) A new generation of the IMAGIC image processing system. J Struct Biol 116(1):17-24.
56. Hohn M, et al. (2007) SPARX, a new environment for Cryo-EM image processing. J Struct Biol 157(1):47-55.
57. Ludtke SJ, Baldwin PR, Chiu W (1999) EMAN: Semiautomated software for highresolution single-particle reconstructions. J Struct Biol 128(1):82-97.
58. Pettersen EF, et al. (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612.
59. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671-675.